UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total Shareholders' Equity Attributable to Bruker Corporation	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests in Consolidated Subsidiaries	Redeemable Noncontrolling Interest	Total
Balance at beginning of period at Dec. 31, 2018	$ 896.6	$ 1.7	$ (401.5)	$ 176.9	$ 1,102.5	$ 17.0	$ 8.5	$ 22.6	$ 905.1
Balance (in shares) at Dec. 31, 2018		156,609,340	16,024,880
Increase (Decrease) in Stockholders' Equity
Stock options exercised	3.1			3.1					3.1
Stock options exercised (in shares)		167,177
Restricted stock units vested (in shares)		35,072
Stock based compensation	2.7			2.7					2.7
Shares issued for acquisition (in shares)		3,087	(3,087)
Cash dividends paid to common stockholders ($0.04 per share)	(6.3)				(6.3)				(6.3)
Consolidated net income (loss)	30.8				30.8		(0.1)	(0.2)	30.7
Other comprehensive income (loss)	(13.7)					(13.7)		(0.4)	(13.7)
Balance at end of period at Mar. 31, 2019	913.2	$ 1.7	$ (401.5)	182.7	1,127.0	3.3	8.4	22.0	921.6
Balance (in shares) at Mar. 31, 2019		156,814,676	16,021,793
Balance at beginning of period at Dec. 31, 2019	906.8	$ 1.7	$ (543.8)	199.7	1,274.7	(25.5)	10.3	21.1	917.1
Balance (in shares) at Dec. 31, 2019		154,155,798	19,346,577
Increase (Decrease) in Stockholders' Equity
Stock options exercised	0.7			0.7					0.7
Stock options exercised (in shares)		30,182
Restricted stock units vested	(0.1)			(0.1)					(0.1)
Restricted stock units vested (in shares)		40,516
Stock based compensation	3.0			3.0					3.0
Acquisition of Hain LifeScience	(1.3)				(1.3)			(20.6)	(1.3)
Cash dividends paid to common stockholders ($0.04 per share)	(6.2)				(6.2)		(1.2)		(7.4)
Consolidated net income (loss)	10.5				10.5		0.1		10.6
Other comprehensive income (loss)	2.2					2.2	(0.2)	$ (0.5)	2.0
Balance at end of period at Mar. 31, 2020	$ 915.6	$ 1.7	$ (543.8)	$ 203.3	$ 1,277.7	$ (23.3)	$ 9.0		$ 924.6
Balance (in shares) at Mar. 31, 2020		154,226,496	19,346,577